A new study on mice published in Nature Neuroscience finds that fingolimod (Novartis brand name Gilenya) a first-in-class sphingosine-1-phosphate-receptor modulator currently used in treating persons with severe relapsing remitting MS, may also have therapeutic value in treating Post Traumatic Stress Disorder (PTSD). The Nature Neuroscience study is titled…
Gilenya
Recommended Posts
- Starting a home bakery looks different with multiple sclerosis
- Lifestyle factors may reduce or fuel inflammation in early MS, study says
- Pain, sleep, stress linked to fatigue severity in relapsing-remitting MS
- Study links MS to greater long-term memory loss over time
- With multiple sclerosis, you don’t get to choose the ladder you climb